Does ketamine mimic aspects of schizophrenic speech? - PubMed (original) (raw)
Randomized Controlled Trial
Does ketamine mimic aspects of schizophrenic speech?
Michael A Covington et al. J Psychopharmacol. 2007 May.
Abstract
Speech disturbances are well-known symptoms contributing to the diagnosis of schizophrenia. Subanesthetic doses of the N-methyl-D-aspartate (NMDA) antagonist ketamine have been reported to produce positive and negative symptoms and cognitive impairments consistent with those seen in schizophrenia. Insofar as this is true, it constitutes evidence that the NMDA system is involved in schizophrenia. It is therefore of interest to know whether ketamine produces speech disturbances like those of schizophrenia. Quantitative computer-aided analysis of apparently normal speech can detect clinically relevant changes and differences that are not noticeable to the human observer. Accordingly, in this study, speech samples were analysed for repetitiousness, idea density, and verb density using software developed by the authors. The samples came from two experiments, a within-subjects study of healthy volunteers given intravenous ketamine versus placebo, and a between-groups study of patients diagnosed with schizophrenia and comparable healthy controls.Our primary hypothesis was that in both schizophrenia and ketamine, repetitiousness would increase, since perserverative speech is a well-known symptom of schizophrenia. Our secondary hypotheses were that in both schizophrenia and ketamine, idea density and verb density would decrease as indicators of cognitive impairment. The primary hypothesis was confirmed in the schizophrenia experiment (between groups) and the ketamine experiment (within subjects). The secondary hypotheses were disconfirmed except that in the ketamine experiment, verb density was significantly lowered. Reduced use of verbs apparently reflects a cognitive impairment of a different type than repetitiousness, and further investigation is needed to determine whether this impairment occurs in psychosis.
Comment in
- Ketamine and schizophrenic speech: more difference than originally reported.
Covington MA, Riedel WJ, Brown C, He C, Morris E, Weinstein S, Semple J, Brown J. Covington MA, et al. J Psychopharmacol. 2009 Jan;23(1):111-2. doi: 10.1177/0269881108091590. Epub 2008 Jun 18. J Psychopharmacol. 2009. PMID: 18562422 No abstract available.
Similar articles
- Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA. Gouzoulis-Mayfrank E, et al. Pharmacopsychiatry. 2005 Nov;38(6):301-11. doi: 10.1055/s-2005-916185. Pharmacopsychiatry. 2005. PMID: 16342002 Clinical Trial. - [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L. Mechri A, et al. Encephale. 2001 Jan-Feb;27(1):53-9. Encephale. 2001. PMID: 11294039 Review. French. - Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.
Heekeren K, Neukirch A, Daumann J, Stoll M, Obradovic M, Kovar KA, Geyer MA, Gouzoulis-Mayfrank E. Heekeren K, et al. J Psychopharmacol. 2007 May;21(3):312-20. doi: 10.1177/0269881107077734. J Psychopharmacol. 2007. PMID: 17591658 Clinical Trial. - Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man.
Boeijinga PH, Soufflet L, Santoro F, Luthringer R. Boeijinga PH, et al. J Psychopharmacol. 2007 May;21(3):321-37. doi: 10.1177/0269881107077768. J Psychopharmacol. 2007. PMID: 17591659 Clinical Trial. - The NMDA antagonist model for schizophrenia: promise and pitfalls.
Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. Abi-Saab WM, et al. Pharmacopsychiatry. 1998 Jul;31 Suppl 2:104-9. doi: 10.1055/s-2007-979354. Pharmacopsychiatry. 1998. PMID: 9754841 Review.
Cited by
- Ketamine administration in healthy volunteers reproduces aberrant agency experiences associated with schizophrenia.
Moore JW, Turner DC, Corlett PR, Arana FS, Morgan HL, Absalom AR, Adapa R, de Wit S, Everitt JC, Gardner JM, Pigott JS, Haggard P, Fletcher PC. Moore JW, et al. Cogn Neuropsychiatry. 2011;16(4):364-81. doi: 10.1080/13546805.2010.546074. Epub 2011 Feb 6. Cogn Neuropsychiatry. 2011. PMID: 21302161 Free PMC article. Clinical Trial. - Automatic measurement of propositional idea density from part-of-speech tagging.
Brown C, Snodgrass T, Kemper SJ, Herman R, Covington MA. Brown C, et al. Behav Res Methods. 2008 May;40(2):540-5. doi: 10.3758/brm.40.2.540. Behav Res Methods. 2008. PMID: 18522065 Free PMC article. - A window into the intoxicated mind? Speech as an index of psychoactive drug effects.
Bedi G, Cecchi GA, Slezak DF, Carrillo F, Sigman M, de Wit H. Bedi G, et al. Neuropsychopharmacology. 2014 Sep;39(10):2340-8. doi: 10.1038/npp.2014.80. Epub 2014 Apr 3. Neuropsychopharmacology. 2014. PMID: 24694926 Free PMC article. Clinical Trial. - Mitochondrial dysfunction and psychiatric disorders.
Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Rezin GT, et al. Neurochem Res. 2009 Jun;34(6):1021-9. doi: 10.1007/s11064-008-9865-8. Epub 2008 Nov 1. Neurochem Res. 2009. PMID: 18979198 Review. - N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?
Kantrowitz JT, Javitt DC. Kantrowitz JT, et al. Brain Res Bull. 2010 Sep 30;83(3-4):108-21. doi: 10.1016/j.brainresbull.2010.04.006. Epub 2010 Apr 24. Brain Res Bull. 2010. PMID: 20417696 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources